サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1426449

消化管間質腫瘍の世界市場レポート 2024

Gastrointestinal Stromal Tumor Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
消化管間質腫瘍の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

消化管間質腫瘍の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には7.1%の年間複合成長率（CAGR）で16億9,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、継続的な調査と医薬品開発、患者中心のヘルスケアの台頭、精密医療の臨床実践への統合、標的療法へのアクセスの増加、ゲノムプロファイリング能力の拡大に起因すると考えられます。予測期間中に予想される主な動向には、研究開発における協力の拡大、診断技術の進歩、共同調査と臨床試験、早期発見と診断への注目の高まり、併用療法の探索などが含まれます。

予想される胃がん症例の増加は、消化管間質腫瘍市場の成長を促進する態勢が整っています。胃がんは、胃の内壁における悪性細胞の制御されない増殖を特徴とし、消化管間質腫瘍（GIST）とは異なりますが、GISTは胃で発生する可能性があります。興味深いことに、2つの別々の腫瘍が1つに融合したGIST患者は、小腸腺がんを含む追加のがんのリスクが高くなります。たとえば、Cancer調査UKは、2023～2025年と2038～2040年の間に英国での胃がんの発生率が12%減少し、年間平均10万人あたり8人の胃がん発生率に達すると予測しています。したがって、胃がんの発生の増加は、消化管間質腫瘍市場を推進する主要な推進力です。

高精度医療に対する需要の高まりにより、消化管間質腫瘍市場の拡大が促進されると予想されます。精密医療は、遺伝やライフスタイルなどの個々の患者の特性に合わせて調整された、的を絞った治療アプローチです。 消化管間質腫瘍の場合、精密医療には、特定の変異を特定する分子プロファイリングが含まれ、イマチニブなどの治療法を導きます。 2022年、食品医薬品局の医薬品評価研究センターは37の新しい分子実体を承認し、そのうち34％が個別化医療として分類されました。この精密医療の採用の増加は、消化管間質腫瘍市場の成長に貢献しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の消化管間質腫瘍市場、治療タイプ別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 化学療法
  • 標的療法
  • その他の治療タイプ
  • 世界の消化管間質腫瘍市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 胃
  • 小腸
  • その他の適応症
  • 世界の消化管間質腫瘍市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • クリニック
  • がん専門治療センター
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の消化管間質腫瘍市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の消化管間質腫瘍市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 消化管間質腫瘍市場の競合情勢
  • 消化管間質腫瘍市場の企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Bayer AG
    • Novartis AG
    • Merck &Co. Inc.

第31章 その他の大手および革新的な企業

  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • AstraZeneca plc
  • Eli Lilly and Company
  • Daiichi Sankyo Co. Ltd.
  • Eisai Co. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Jiangsu Hengrui Medicine Co. Ltd.
  • Exelixis Inc.
  • NATCO Pharma Ltd.
  • Blueprint Medicines Corporation
  • Array BioPharma Inc.
  • Deciphera Pharmaceuticals Inc.
  • Ono Pharmaceutical Co. Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13461

A gastrointestinal stromal tumor (GIST) is a rare type of non-epithelial tumor that originates in the gastrointestinal (GI) tract. These tumors most commonly develop in the stomach or the small intestine, although they can occur anywhere along the GI tract, from the esophagus to the rectum.

The main treatment modalities for gastrointestinal stromal tumors include chemotherapy, targeted therapy, and others. Chemotherapy is a medical treatment that utilizes potent drugs to target and eliminate rapidly dividing cells in the body, including cancer cells. It is prescribed for various indications such as those affecting the stomach, small intestine, and other parts of the GI tract. Different end-users, including hospitals, clinics, specialized cancer treatment centers, and others, may administer chemotherapy as part of the treatment regimen.

The gastrointestinal stromal tumor market research report is one of a series of new reports from The Business Research Company that provides gastrointestinal stromal tumor market statistics, including gastrointestinal stromal tumor industry global market size, regional shares, competitors with a gastrointestinal stromal tumor market share, detailed gastrointestinal stromal tumor market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal stromal tumor industry. This gastrointestinal stromal tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastrointestinal stromal tumor market size has grown strongly in recent years. It will grow from $1.18 billion in 2023 to $1.28 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth observed in the historical period can be attributed to increased awareness and early diagnosis, the emergence of targeted therapies, enhanced surgical techniques, the development of personalized medicine, and improvements in supportive care.

The gastrointestinal stromal tumor market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The anticipated growth in the forecast period can be attributed to continued research and drug development, a rise in patient-centric healthcare, the integration of precision medicine into clinical practice, increasing access to targeted therapies, and expanding genomic profiling capabilities. Key trends expected in the forecast period include growing collaboration in research and development, advancements in diagnostic technologies, collaborative research and clinical trials, increased focus on early detection and diagnosis, and exploration of combination therapies.

The anticipated increase in stomach cancer cases is poised to drive the growth of the gastrointestinal stromal tumor market. Stomach cancer, characterized by the uncontrolled growth of malignant cells in the stomach lining, is distinct from gastrointestinal stromal tumors (GISTs), although GISTs can occur in the stomach. Interestingly, individuals with GISTs who develop two separate tumors that merge into one have an elevated risk of additional cancers, including small bowel adenocarcinoma. For example, Cancer Research UK projects a 12% decline in stomach cancer incidence in the UK between 2023-2025 and 2038-2040, reaching an average of 8 cases per 100,000 people annually. Thus, the increasing occurrence of stomach cancer is a key driver propelling the gastrointestinal stromal tumor market.

The growing demand for precision medicine is expected to fuel the expansion of the gastrointestinal stromal tumor market. Precision medicine, tailored to individual patient characteristics such as genetics and lifestyle, is a targeted approach to medical treatment. In the case of gastrointestinal stromal tumors, precision medicine involves molecular profiling to identify specific mutations, guiding therapies such as imatinib. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research approved 37 new molecular entities, with 34% classified as personalized medicines. This rise in precision medicine adoption contributes to the growth of the gastrointestinal stromal tumor market.

The limitation of health awareness and literacy is anticipated to hinder the growth of the gastrointestinal stromal tumors (GIST) market. Limited awareness of safety regulations and guidelines can lead to accidents and injuries when handling drums, similar to the constraints faced in gastrointestinal stromal tumor management due to a lack of awareness about chronic disease treatment. Enhancing awareness within healthcare and research communities and among the general public is crucial to addressing cancer as a significant health issue. Therefore, the lack of health awareness and literacy significantly constrains the growth potential of the gastrointestinal stromal tumors market, hindering improvements in patient outcomes.

Major companies in the gastrointestinal stromal tumor market are introducing innovative drugs such as QINLOCK (Ripretinib) to cater to larger customer bases, boost sales, and increase revenue. QINLOCK (Ripretinib) is a prescription medicine approved for the treatment of advanced gastrointestinal stromal tumor (GIST). For instance, Zai Lab Ltd, a China-based biotechnology company, announced the approval of QINLOCK (Ripretinib) by the National Medical Products Administration (NMPA) of China in March 2021. This drug is prescribed for the treatment of advanced GIST in adult patients who have previously undergone treatment with three or more kinase inhibitors, including imatinib.

In June 2022, Immatics N.V., a Germany-based biotechnology company, formed a partnership with Bristol Myers Squibb to develop gamma delta allogeneic cell therapy programs. This collaboration aims to create advanced cancer immunotherapies with the potential to enhance the treatment of various cancers, including gastrointestinal stromal tumors (GISTs). Bristol Myers Squibb, a US-based pharmaceutical company, is actively involved in developing treatments related to GISTs.

Major companies operating in the gastrointestinal stromal tumor market report are Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., NATCO Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Advenchen Laboratories LLC, Arog Pharmaceuticals Inc., AB Sciences S.A.

North America was the largest region in the gastrointestinal stromal tumor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal stromal tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the gastrointestinal stromal tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The gastrointestinal stromal tumor market includes revenues earned by entities by providing services such as diagnostic services, pathology services, pathology services, and pathology services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal stromal tumor market also includes sales of targeted therapy, chemotherapy, radiation therapy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastrointestinal Stromal Tumor Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastrointestinal stromal tumor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastrointestinal stromal tumor? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastrointestinal stromal tumor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Treatment Type: Chemotherapy; Targeted Therapy; Other Treatment Types
  • 2) By Indication: Stomach; Small Intestine; Others Indications
  • 3) By End-User: Hospitals; Clinics; Specialized Cancer Treatment Centers; Other End-Users
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Bayer AG; Novartis AG; Merck & Co. Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gastrointestinal Stromal Tumor Market Characteristics

3. Gastrointestinal Stromal Tumor Market Trends And Strategies

4. Gastrointestinal Stromal Tumor Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Gastrointestinal Stromal Tumor Market Size and Growth

  • 5.1. Global Gastrointestinal Stromal Tumor Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Gastrointestinal Stromal Tumor Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Gastrointestinal Stromal Tumor Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Gastrointestinal Stromal Tumor Market Segmentation

  • 6.1. Global Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chemotherapy
  • Targeted Therapy
  • Other Treatment Types
  • 6.2. Global Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Stomach
  • Small Intestine
  • Others Indications
  • 6.3. Global Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Specialized Cancer Treatment Centers
  • Other End-Users

7. Gastrointestinal Stromal Tumor Market Regional And Country Analysis

  • 7.1. Global Gastrointestinal Stromal Tumor Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Gastrointestinal Stromal Tumor Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Gastrointestinal Stromal Tumor Market

  • 8.1. Asia-Pacific Gastrointestinal Stromal Tumor Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Gastrointestinal Stromal Tumor Market

  • 9.1. China Gastrointestinal Stromal Tumor Market Overview
  • 9.2. China Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Gastrointestinal Stromal Tumor Market

  • 10.1. India Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Gastrointestinal Stromal Tumor Market

  • 11.1. Japan Gastrointestinal Stromal Tumor Market Overview
  • 11.2. Japan Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Gastrointestinal Stromal Tumor Market

  • 12.1. Australia Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Gastrointestinal Stromal Tumor Market

  • 13.1. Indonesia Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Gastrointestinal Stromal Tumor Market

  • 14.1. South Korea Gastrointestinal Stromal Tumor Market Overview
  • 14.2. South Korea Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Gastrointestinal Stromal Tumor Market

  • 15.1. Western Europe Gastrointestinal Stromal Tumor Market Overview
  • 15.2. Western Europe Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Gastrointestinal Stromal Tumor Market

  • 16.1. UK Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Gastrointestinal Stromal Tumor Market

  • 17.1. Germany Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Gastrointestinal Stromal Tumor Market

  • 18.5. France Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.6. France Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.7. France Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Gastrointestinal Stromal Tumor Market

  • 19.9. Italy Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Gastrointestinal Stromal Tumor Market

  • 20.13. Spain Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Gastrointestinal Stromal Tumor Market

  • 21.1. Eastern Europe Gastrointestinal Stromal Tumor Market Overview
  • 21.2. Eastern Europe Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Gastrointestinal Stromal Tumor Market

  • 22.1. Russia Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Gastrointestinal Stromal Tumor Market

  • 23.1. North America Gastrointestinal Stromal Tumor Market Overview
  • 23.2. North America Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Gastrointestinal Stromal Tumor Market

  • 24.1. USA Gastrointestinal Stromal Tumor Market Overview
  • 24.2. USA Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Gastrointestinal Stromal Tumor Market

  • 25.1. Canada Gastrointestinal Stromal Tumor Market Overview
  • 25.2. Canada Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Gastrointestinal Stromal Tumor Market

  • 26.1. South America Gastrointestinal Stromal Tumor Market Overview
  • 26.2. South America Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Gastrointestinal Stromal Tumor Market

  • 27.1. Brazil Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Gastrointestinal Stromal Tumor Market

  • 28.1. Middle East Gastrointestinal Stromal Tumor Market Overview
  • 28.2. Middle East Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Gastrointestinal Stromal Tumor Market

  • 29.1. Africa Gastrointestinal Stromal Tumor Market Overview
  • 29.2. Africa Gastrointestinal Stromal Tumor Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Gastrointestinal Stromal Tumor Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Gastrointestinal Stromal Tumor Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Gastrointestinal Stromal Tumor Market Competitive Landscape And Company Profiles

  • 30.1. Gastrointestinal Stromal Tumor Market Competitive Landscape
  • 30.2. Gastrointestinal Stromal Tumor Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bayer AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Merck & Co. Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Gastrointestinal Stromal Tumor Market Other Major And Innovative Companies

  • 31.1. GlaxoSmithKline plc
  • 31.2. Bristol-Myers Squibb Company
  • 31.3. Sanofi S.A.
  • 31.4. AstraZeneca plc
  • 31.5. Eli Lilly and Company
  • 31.6. Daiichi Sankyo Co. Ltd.
  • 31.7. Eisai Co. Ltd.
  • 31.8. Sun Pharmaceutical Industries Limited
  • 31.9. Jiangsu Hengrui Medicine Co. Ltd.
  • 31.10. Exelixis Inc.
  • 31.11. NATCO Pharma Ltd.
  • 31.12. Blueprint Medicines Corporation
  • 31.13. Array BioPharma Inc.
  • 31.14. Deciphera Pharmaceuticals Inc.
  • 31.15. Ono Pharmaceutical Co. Ltd.

32. Global Gastrointestinal Stromal Tumor Market Competitive Benchmarking

33. Global Gastrointestinal Stromal Tumor Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Gastrointestinal Stromal Tumor Market

35. Gastrointestinal Stromal Tumor Market Future Outlook and Potential Analysis

  • 35.1 Gastrointestinal Stromal Tumor Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Gastrointestinal Stromal Tumor Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Gastrointestinal Stromal Tumor Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer